These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 24782291)

  • 1. Reversing vascular dysfunction in rheumatoid arthritis: improved augmentation index but not endothelial function with peroxisome proliferator-activated receptor γ agonist therapy.
    Ormseth MJ; Oeser AM; Cunningham A; Bian A; Shintani A; Solus J; Tanner SB; Stein CM
    Arthritis Rheumatol; 2014 Sep; 66(9):2331-8. PubMed ID: 24782291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial.
    Ormseth MJ; Oeser AM; Cunningham A; Bian A; Shintani A; Solus J; Tanner S; Stein CM
    Arthritis Res Ther; 2013; 15(5):R110. PubMed ID: 24020899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The peroxisome proliferator activated receptor-γ pioglitazone improves vascular function and decreases disease activity in patients with rheumatoid arthritis.
    Marder W; Khalatbari S; Myles JD; Hench R; Lustig S; Yalavarthi S; Parameswaran A; Brook RD; Kaplan MJ
    J Am Heart Assoc; 2013 Nov; 2(6):e000441. PubMed ID: 24252844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men.
    Ryan KE; McCance DR; Powell L; McMahon R; Trimble ER
    Atherosclerosis; 2007 Oct; 194(2):e123-30. PubMed ID: 17145061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors.
    Campia U; Matuskey LA; Panza JA
    Circulation; 2006 Feb; 113(6):867-75. PubMed ID: 16461819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of insulin sensitivity treatment with pioglitazone on endothelial function in non-diabetic patients with arterial hypertension.
    Schneider F; Vossler S; Franke S; Bär F; Konrad T
    Int J Clin Pharmacol Ther; 2009 May; 47(5):311-20. PubMed ID: 19473593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes.
    Sourij H; Zweiker R; Wascher TC
    Diabetes Care; 2006 May; 29(5):1039-45. PubMed ID: 16644634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPARγ activation does not affect endothelin activity in non-diabetic patients with hypertension or hypercholesterolemia.
    Campia U; Matuskey LA; Tesauro M; Cardillo C; Panza JA
    Atherosclerosis; 2014 Jun; 234(2):436-40. PubMed ID: 24769306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance.
    Werner C; Kamani CH; Gensch C; Böhm M; Laufs U
    Diabetes; 2007 Oct; 56(10):2609-15. PubMed ID: 17623816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes.
    Martens FM; Visseren FL; de Koning EJ; Rabelink TJ
    J Cardiovasc Pharmacol; 2005 Dec; 46(6):773-8. PubMed ID: 16306801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone on Peripheral Vessel Function and Clinical Parameters in Nondiabetic Patients: A Double-Center, Randomized Controlled Pilot Trial.
    Christoph M; Herold J; Berg-Holldack A; Rauwolf T; Ziemssen T; Schmeisser A; Weinert S; Ebner B; Ibrahim K; Strasser RH; Braun-Dullaeus RC
    Cardiology; 2015; 131(3):165-71. PubMed ID: 25967848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the PPAR-γ Agonist Pioglitazone in Mild Asthma: A Double-Blind Randomized Controlled Trial.
    Anderson JR; Mortimer K; Pang L; Smith KM; Bailey H; Hodgson DB; Shaw DE; Knox AJ; Harrison TW
    PLoS One; 2016; 11(8):e0160257. PubMed ID: 27560168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosiglitazone does not improve vascular function in subjects with chronic kidney disease.
    Chan DT; Watts GF; Irish AB; Dogra GK
    Nephrol Dial Transplant; 2011 Nov; 26(11):3543-9. PubMed ID: 21378155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone.
    Martens FM; Rabelink TJ; op 't Roodt J; de Koning EJ; Visseren FL
    Eur Heart J; 2006 Jul; 27(13):1605-9. PubMed ID: 16762982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension.
    Barac A; Campia U; Matuskey LA; Lu L; Panza JA
    Am J Cardiol; 2008 Apr; 101(7):980-5. PubMed ID: 18359318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy.
    Mäki-Petäjä KM; Hall FC; Booth AD; Wallace SM; Yasmin ; Bearcroft PW; Harish S; Furlong A; McEniery CM; Brown J; Wilkinson IB
    Circulation; 2006 Sep; 114(11):1185-92. PubMed ID: 16952987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects.
    Pfützner A; Schneider CA; Forst T
    Expert Rev Cardiovasc Ther; 2006 Jul; 4(4):445-59. PubMed ID: 16918264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pioglitazone ameliorates endothelial dysfunction in those with impaired glucose regulation among the first-degree relatives of type 2 diabetes mellitus patients.
    Yu X; Chen P; Wang H; Zhu T
    Med Princ Pract; 2013; 22(2):156-60. PubMed ID: 22964975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized placebo controlled double blind crossover study of pioglitazone on left ventricular diastolic function in type 2 diabetes.
    Hughes AD; Park C; March K; Coady E; Khir A; Chaturvedi N; Thom SA
    Int J Cardiol; 2013 Aug; 167(4):1329-32. PubMed ID: 22525343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes.
    McMahon GT; Plutzky J; Daher E; Bhattacharyya T; Grunberger G; DiCarli MF
    Diabetes Care; 2005 May; 28(5):1145-50. PubMed ID: 15855580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.